How to ensure accurate NeuroQuant® processing results

In this post, I review additional causes affecting goodness of fit which can result in NeuroQuant being unable to segment specific brain structures and issuing a processing error message. Previous posts discussed why contrast agents are not used to achieve quality segmentation with NeuroQuant, and examined why good alignment to atlas is necessary for accurate NeuroQuant output.

Ensuring proper processing is an important factor in NeuroQuant’s analysis process. To achieve its high quality segmentation results, NeuroQuant verifies each patient’s brain image can be processed correctly. This safeguards the accuracy of the segmentation results and therefore, the accuracy of the calculated volumes.

Patients who have shunts, implants or other artifacts or inherent abnormalities, can potentially generate segmentation misregistration. To prevent such errors and protect the accuracy of the results, NeuroQuant prevents analysis when such artifacts or anatomical anomalies are present.

In some cases, such as the first example below, a shunt in the patient’s brain made good alignment to atlas impossible, resulting in a processing failure.

Cortechs.ai | How to ensure accurate NeuroQuant® processing resultsIn the second example, a patient’s excess cranial tissue prevented proper processing and resulted in an error message.

Cortechs.ai | How to ensure accurate NeuroQuant® processing resultsMore information about using and processing NeuroQuant can be found here.

More Resources

09/01/2026

Quantifying What Matters: Advancing Alzheimer’s Imaging with NeuroQuant®

Explore how quantitative imaging is transforming Alzheimer’s care, from structural volumetrics and amyloid PET to treatment monitoring with NeuroQuant®.

08/19/2026

Brain Metastases Imaging Insights from SNO/ASCO 2026

Explore key insights from SNO/ASCO 2026 on brain metastases imaging, including lesion tracking, volumetric analysis, SRS workflows, and automated segmentation.

08/18/2026

Cortechs.ai Announces FDA Clearance for NeuroQuant® PET: Advancing Molecular Imaging for Cognitive Impairment

NeuroQuant® PET receives FDA 510(k) clearance, advancing quantitative PET imaging for cognitive impairment.

08/04/2026

Cortechs.ai Expands European CE Marking Across AI Imaging Platform, Accelerating Global Growth

Cortechs.ai expands EU CE Marking for the latest NeuroQuant®, NeuroQuant® Brain Tumor, and OnQ™ Prostate, advancing global AI imaging innovation

07/29/2026

Read Your Segmentations in the Same Space You Read the Study: Native Space Outputs in NeuroQuant v5.3.0

Review lesion segmentations directly on your original MRI images with NeuroQuant® v5.3.0.

07/23/2026

What AAIC 2026 Told Us About the Future of Dementia Imaging — And Where NeuroQuant Fits

Quantitative MRI brain volumetry with NeuroQuant.
Scroll to Top